Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All aviptadil studies
..
Feedback
Home
c19early.org COVID-19 treatment researchAviptadilAviptadil (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 aviptadil studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -5% 3 775 Improvement, Studies, Patients Relative Risk Mortality 16% 2 657 Progression 15% 2 657 RCTs -5% 3 775 RCT mortality 16% 2 657 Peer-reviewed 16% 2 657 Late -5% 3 775 Aviptadil for COVID-19 c19early.org May 2025 Favorsaviptadil Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Late treatment -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk All studies -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk 3 aviptadil COVID-19 studies c19early.org May 2025 Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 mortality results c19early.org May 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 serious outcomes c19early.org May 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.018 Late treatment -79% 1.79 [1.12-2.94] 51 (n) 67 (n) 79% higher risk All studies -79% 1.79 [1.12-2.94] 51 (n) 67 (n) 79% higher risk 1 aviptadil COVID-19 recovery result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.018 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Late treatment -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk All studies -5% 1.05 [0.63-1.74] 46/413 30/362 5% higher risk 3 aviptadil COVID-19 Randomized Controlled Trials c19early.org May 2025 Tau​2​ = 0.17, I​2​ = 82.6%, p = 0.87 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 RCT mortality results c19early.org May 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 Improvement, RR [CI] Treatment Control TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Late treatment 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk All studies 16% 0.84 [0.52-1.35] 46/362 30/295 16% lower risk 2 aviptadil COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 0.09, I​2​ = 77.2%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors aviptadil Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY Gibbs (DB RCT) -79% 1.79 [1.12-2.94] no recov. 51 (n) 67 (n) Improvement, RR [CI] Treatment Control COVID-AIV Youssef (DB RCT) 35% 0.65 [0.39-0.97] death 46/131 30/65 COVID-AIV Youssef (DB RCT) 20% 0.80 [0.52-1.13] progression 59/131 31/65 TESICO Brown (DB RCT) -6% 1.06 [0.79-1.42] death 231 (n) 230 (n) TESICO Brown (DB RCT) 10% 0.90 [0.65-1.25] progression 231 (n) 230 (n) Aviptadil COVID-19 outcomes c19early.org May 2025 Favors aviptadil Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0